3.
section 3.1 |
Analysis of
submissions from
Interested Persons
appendix 2
Outcomes of Consultation: Submissions
from Interested Persons
Section contents
3.
Analysis of submissions from Interested
Persons
28
3.1
Strategy: an introduction
29
Report Appendix 2 | Royal Commission on Genetic Modification
Section 3: Analysis o f Submissions from Interested Persons
| H1 | p29
Royal Commission on Genetic M odification | Report Appendix 2
Section contents
3.1 Strategy: an introduction
3.2 Strategic options
3.3 Strategic issues
3.4 Strategic outcomes
3.5 Statutory and regulatory processes
3.6 Where, how, and for what purpose ...
3.7 Evidence and uncertainty
3.8 Risks and benefits
3.9 International obligations and implications
3.10 Liability issues
3.11 Intellectual property issues
3.12 Responsibilities under the Treaty of Waitangi
3.13 Global developments and issues
3.14 Opportunities from use or avoidance
3.15 Areas of public interest: an introduction
3.16 Areas of public interest: human health issues
3.17 Areas of public interest: environmental matters
3.18 Areas of public interest: economic matters
3.19 Areas of public interest: cultural and ethical concerns
3.1 Strategy: an introduction
The following three sections discuss three Warrant items concerning strategy.
The Warrant items are:
(1) the strategic options available to enable New Zealand to address, now and in the
future, genetic modification, genetically modified organisms and products
(k) the key strategic issues drawing on ethical, cultural, environmental, social, and
economic risks and benefits arising form the use of genetic modification, genetically
modified organisms, and products
p30 |
Section 3: Analy sis o f Submissions from Interested P ersons
Report Appendix 2 | Royal Commission on Genetic M odification
(m) the range of strategic outcomes for the future application or avoidance of genetic
modification, genetically modified organisms, and products in New Zealand
Strategic matters received considerable comment from submitters. Seventy-eight
submitters commented on Warrant item (1) strategic `options', 39 on Warrant
item (k) strategic `issues', and 37 on Warrant item (m) strategic `outcomes'.
Strategic `options', `issues' and `outcomes' have been addressed simultaneously to
ensure the scope of submitters' comment is fully captured in relevant discussion.
Where appropriate, comments across the three Warrant items have been grouped
together. Submitters' comments suggest that there was no uniform and consistent
understanding of the terms strategic `options', strategic `issues' and strategic
`outcomes'. Hence submitters have interpreted, defined and delineated these
terms in different ways. For the purposes of this report, submitters' comments
have been drawn together in the following manner.
Strategic options includes the broad-based, overall philosophy that might guide
the direction of New Zealand policy for genetic modification. Strategic options
include the various pathways, or courses of action, available to New Zealand.
Strategic options available include, for example, an option for a totally `genetic
modification free' New Zealand, the option of a system which encompasses use of
genetic modification technology in some areas but not in others, or the option of a
widespread use of genetic modification in New Zealand.
Strategic issues discusses the general questions that arise when a particular course
of action is followed. They can be seen as the linkage between the strategic options
being pursued, and the resultant outcomes. The Warrant item mentions strategic
issues that involve ethical, social, cultural, environmental, social and economic
risks and benefits. In this report, submitter views on what are strategic issues
includes discussion of these points with respect to considerations of `acceptability',
`choice', `risk management' and `opportunities' to be gained or lost.
Strategic outcomes comprises the range of end results that might be specifically
sought, or might result from, the application or avoidance of genetic modification,
genetically modified organisms and products in New Zealand. Outcomes include,
for example, the results from the use or the avoidance of genetic modification in
the areas of health, environment, production, research, culture and ethics.
In brief, in selecting a particular course of action, or pathway (strategic option),
certain questions and considerations are considered (strategic issues) in order to
achieve the final goal or end result (strategic outcome).